المؤلفون: Liu, X, George, GC, Tsimberidou, AM, Naing, A, Wheler, JJ, Kopetz, S, Fu, S, Piha-Paul, SA, Eng, C, Falchook, GS, Janku, F, Garrett, C, Karp, D, Kurzrock, R, Zinner, R, Raghav, K, Subbiah, V, Hess, K, Meric-Bernstam, F, Hong, DS, Overman, MJ

المصدر: BMC Cancer. 15(1)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Digestive Diseases, Clinical Research, Colo-Rectal Cancer, Adult, Aged, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Cetuximab, Colorectal Neoplasms, Disease-Free Survival, ErbB Receptors, Erlotinib Hydrochloride, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Panitumumab, Proto-Oncogene Proteins p21(ras), Retreatment, Anti-EGFR treatment, KRAS-wt CRC, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Epidemiology

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/05594475

المؤلفون: Park, H, Garrido-Laguna, I, Naing, A, Fu, S, Falchook, GS, Piha-Paul, SA, Wheler, JJ, Hong, DS, Tsimberidou, AM, Subbiah, V, Zinner, RG, Kaseb, AO, Patel, S, Fanale, MA, Velez-Bravo, VM, Meric-Bernstam, F, Kurzrock, R, Janku, F

المصدر: Oncotarget, vol 7, iss 41
Park, H; Garrido-Laguna, I; Naing, A; Fu, S; Falchook, GS; Piha-Paul, SA; et al.(2016). Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. ONCOTARGET, 7(41), 67521-67531. doi: 10.18632/oncotarget.11750. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/1dp7g79p

مصطلحات موضوعية: Sirolimus, Adult, Male, Vorinostat, Maximum Tolerated Dose, Adolescent, TOR Serine-Threonine Kinases, Oncology and Carcinogenesis, Middle Aged, phase I, Hydroxamic Acids, Histone Deacetylase Inhibitors, Young Adult, HDAC, hemic and lymphatic diseases, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, mTOR, Humans, Female, Aged

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::512319f3ff14299dfb14919f0d8072de
https://escholarship.org/uc/item/1dp7g79p

المؤلفون: Ballhausen A; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.; Medical Department, Division of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Wheler JJ; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Karp DD; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Piha-Paul SA; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Fu S; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Pant S; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Tsimberidou AM; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Hong DS; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Subbiah V; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Holley VR; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Huang HJ; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Brewster AM; Division of Cancer Medicine, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Koenig KB; Division of Cancer Medicine, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ibrahim NK; Division of Cancer Medicine, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Meric-Bernstam F; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Janku F; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas. fjanku@mdanderson.org.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Mar 01; Vol. 27 (5), pp. 1247-1255. Date of Electronic Publication: 2020 Oct 28.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Breast Neoplasms/*drug therapy , Neoplasms/*drug therapy , Receptors, Estrogen/*metabolism , Receptors, Progesterone/*metabolism, Adult ; Aged ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Everolimus/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Letrozole/administration & dosage ; Male ; Middle Aged ; Neoplasms/metabolism ; Neoplasms/pathology ; Non-Randomized Controlled Trials as Topic ; Prognosis ; Receptor, ErbB-2 ; Retrospective Studies ; Survival Rate ; Trastuzumab/administration & dosage

المؤلفون: Janku F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. fjanku@mdanderson.org., Park H; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Internal Medicine (Division of Oncology), Washington University School of Medicine, St. Louis, Missouri., Call SG; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Madwani K; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Oki Y; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hong DS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Naing A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Velez-Bravo VM; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Barnes TG; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hagemeister FB; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Falchook GS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Karp DD; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wheler JJ; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Piha-Paul SA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Garrido-Laguna I; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shpall EJ; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fayad LE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Neelapu SS; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kurzrock R; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fanale MA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Nov 01; Vol. 26 (21), pp. 5579-5587. Date of Electronic Publication: 2020 Oct 14.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Everolimus/*administration & dosage , Histone Deacetylases/*genetics , Hodgkin Disease/*drug therapy , Sirolimus/*administration & dosage , TOR Serine-Threonine Kinases/*genetics , Vorinostat/*administration & dosage, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols ; Brentuximab Vedotin/administration & dosage ; Dose-Response Relationship, Drug ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Drug-Related Side Effects and Adverse Reactions/pathology ; Everolimus/adverse effects ; Female ; Hematopoietic Stem Cell Transplantation ; Histone Deacetylase Inhibitors/administration & dosage ; Histone Deacetylase Inhibitors/adverse effects ; Humans ; Male ; Middle Aged ; Recurrence ; Sirolimus/adverse effects ; Stem Cell Transplantation ; TOR Serine-Threonine Kinases/antagonists & inhibitors ; Vorinostat/adverse effects ; Young Adult

المؤلفون: Tsimberidou AM; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. atsimber@mdanderson.org., Hong DS; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Wheler JJ; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; Current Address: TScan Therapeutics, Waltham, USA., Falchook GS; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; Current Address: Sarah Cannon Research Institute, Nashville, USA., Janku F; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Naing A; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Fu S; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Piha-Paul S; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Cartwright C; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Broaddus RR; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Nogueras Gonzalez GM; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA., Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Kurzrock R; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; Current Address: Moores Cancer Center-University of California San Diego, San Diego, USA.

المصدر: Journal of hematology & oncology [J Hematol Oncol] 2019 Dec 30; Vol. 12 (1), pp. 145. Date of Electronic Publication: 2019 Dec 30.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Molecular Targeted Therapy*, Biomarkers, Tumor/*genetics , Liver Neoplasms/*mortality , Neoplasms/*mortality , Precision Medicine/*methods , Protein Kinase Inhibitors/*therapeutic use , Protein Kinases/*genetics, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/antagonists & inhibitors ; Case-Control Studies ; Clinical Trials, Phase I as Topic ; Female ; Follow-Up Studies ; Humans ; Liver Neoplasms/drug therapy ; Liver Neoplasms/secondary ; Male ; Middle Aged ; Neoplasms/drug therapy ; Neoplasms/pathology ; Prognosis ; Protein Kinases/chemistry ; Response Evaluation Criteria in Solid Tumors ; Survival Rate ; Young Adult

المؤلفون: Sharman JP; Willamette Valley Cancer Institute and Research Center/US Oncology Research, 520 Country Club Rd., Eugene, OR, 97401, USA. Jeff.Sharman@usoncology.com.; US Oncology Research, Houston, TX, USA. Jeff.Sharman@usoncology.com., Wheler JJ; The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA., Einhorn L; Indiana University Division of Hematology and Oncology, 535 Barnhill Dr, Indianapolis, IN, 46202, USA., Dowlati A; Department of Medicine - Hematology and Oncology, University Hospitals Case Medical Center, 11100 Euclid Ave., Cleveland, OH, 44106, USA., Shapiro GI; Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, 02215, USA., Hilton J; Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, 02215, USA.; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, 501 Smyth Road, Ottawa, Ontario, K1H 8L6, Canada.; Ottawa Hospital Research Institute, 501 Smyth, Box 511, Ottawa, Ontario, K1H 8L6, Canada., Burke JM; US Oncology Research, Houston, TX, USA.; Rocky Mountain Cancer Centers, 1700 South Potomac St., Aurora, CO, 80012, USA., Siddiqi T; City of Hope National Medical Center, 1500 East Duarte Rd., Duarte, CA, 91010, USA., Whiting N; Seattle Genetics, Inc., 21823 30th Dr. SE, Bothell, WA, 98021, USA., Jalal SI; Indiana University Division of Hematology and Oncology, 535 Barnhill Dr, Indianapolis, IN, 46202, USA.

المصدر: Investigational new drugs [Invest New Drugs] 2019 Aug; Vol. 37 (4), pp. 738-747. Date of Electronic Publication: 2019 Apr 16.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents, Immunological/*therapeutic use , Brentuximab Vedotin/*therapeutic use , Ki-1 Antigen/*metabolism , Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Immunological/adverse effects ; Brentuximab Vedotin/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Neoplasms/metabolism ; Treatment Outcome ; Young Adult

المؤلفون: Aghajanian C; Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center (MSK), 300 East 66th Street, New York, NY, 10065, USA. aghajanc@mskcc.org.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. aghajanc@mskcc.org., Bell-McGuinn KM; Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center (MSK), 300 East 66th Street, New York, NY, 10065, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.; Eli Lilly and Company, Indianapolis, IN, USA., Burris HA 3rd; Sarah Cannon Research Institute, Nashville, TN, USA.; Tennessee Oncology, Nashville, TN, USA., Siu LL; Princess Margaret Cancer Centre, Toronto, Canada., Stayner LA; Princess Margaret Cancer Centre, Toronto, Canada., Wheler JJ; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hong DS; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kurkjian C; Sarah Cannon Research Institute, Nashville, TN, USA.; Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA., Pant S; Sarah Cannon Research Institute, Nashville, TN, USA.; Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA., Santiago-Walker A; GlaxoSmithKline, Collegeville, PA, USA.; Janssen, Lansdale, PA, USA., Gauvin JL; GlaxoSmithKline, Collegeville, PA, USA.; Novartis Pharmaceuticals, Orlanda, Florida, USA., Antal JM; GlaxoSmithKline, Collegeville, PA, USA.; MedImmune, Gaithersburg, MD, USA., Opalinska JB; GlaxoSmithKline, Collegeville, PA, USA.; Boehringer-Ingelheim, Ridgefield, CT, USA., Morris SR; GlaxoSmithKline, Collegeville, PA, USA.; MedImmune, Gaithersburg, MD, USA., Infante JR; Sarah Cannon Research Institute, Nashville, TN, USA.; Tennessee Oncology, Nashville, TN, USA.

المصدر: Investigational new drugs [Invest New Drugs] 2018 Dec; Vol. 36 (6), pp. 1016-1025. Date of Electronic Publication: 2018 Apr 03.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

مواضيع طبية MeSH: Diamines/*pharmacokinetics , Diamines/*therapeutic use , Neoplasms/*drug therapy , Protein Kinase Inhibitors/*pharmacokinetics , Protein Kinase Inhibitors/*therapeutic use , Proto-Oncogene Proteins c-akt/*antagonists & inhibitors , Pyrazoles/*pharmacokinetics , Pyrazoles/*therapeutic use, Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Cohort Studies ; Diamines/administration & dosage ; Diamines/adverse effects ; Dose-Response Relationship, Drug ; Female ; Humans ; Male ; Middle Aged ; Mutation/genetics ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Proto-Oncogene Proteins c-akt/metabolism ; Pyrazoles/administration & dosage ; Pyrazoles/adverse effects

المؤلفون: Chawla A; , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX., Janku F; , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX., Wheler JJ; , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX., Miller VA; , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX., Ryan J; , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX., Anhorn R; , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX., Zhou Z; , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX., Signorovitch J; , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX.

المصدر: JCO precision oncology [JCO Precis Oncol] 2018 Nov 02; Vol. 2. Date of Electronic Publication: 2018 Nov 02 (Print Publication: 2018).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: eCollection Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: PubMed not MEDLINE

المؤلفون: Sakamuri D; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Glitza IC; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Betancourt Cuellar SL; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Fu S; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Tsimberidou AM; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Wheler JJ; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Hong DS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Naing A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Falchook GS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.; Sarah Cannon Research Institute at HealthONE, Denver, Colorado., Fanale MA; Department of Lymphoma and Myeloma Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Cabanillas ME; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas., Janku F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas. fjanku@mdanderson.org.

المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2018 Mar; Vol. 17 (3), pp. 671-676. Date of Electronic Publication: 2017 Dec 13.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Neoplasms/*drug therapy , Outcome Assessment, Health Care/*methods , Outcome Assessment, Health Care/*statistics & numerical data, Adult ; Aged ; Anemia/chemically induced ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; CTLA-4 Antigen/immunology ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Exanthema/chemically induced ; Female ; Humans ; Ipilimumab/administration & dosage ; Ipilimumab/adverse effects ; Ipilimumab/immunology ; Lenalidomide/administration & dosage ; Lenalidomide/adverse effects ; Male ; Middle Aged ; Neoplasms/classification ; Neoplasms/genetics ; Young Adult

المؤلفون: Drilon A; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York. drilona@mskcc.org., Siena S; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.; Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano, Milan, Italy., Ou SI; Chao Family Comprehensive Cancer Center, University of California, Irvine, California., Patel M; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, Florida., Ahn MJ; Samsung Medical Center, Seoul, Korea., Lee J; Samsung Medical Center, Seoul, Korea., Bauer TM; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee., Farago AF; Massachusetts General Hospital, Boston, Massachusetts., Wheler JJ; The University of Texas MD Anderson Cancer Center, Houston, Texas., Liu SV; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC., Doebele R; University of Colorado Cancer Center, Aurora, Colorado., Giannetta L; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Cerea G; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Marrapese G; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Schirru M; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Amatu A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Bencardino K; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Palmeri L; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Sartore-Bianchi A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Vanzulli A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.; Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano, Milan, Italy., Cresta S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Damian S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Duca M; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Ardini E; Nerviano Medical Sciences s.r.l, Milan, Italy., Li G; Ignyta, Inc., San Diego, California., Christiansen J; Ignyta, Inc., San Diego, California., Kowalski K; Ignyta, Inc., San Diego, California., Johnson AD; Ignyta, Inc., San Diego, California., Patel R; Ignyta, Inc., San Diego, California., Luo D; Ignyta, Inc., San Diego, California., Chow-Maneval E; Ignyta, Inc., San Diego, California., Hornby Z; Ignyta, Inc., San Diego, California., Multani PS; Ignyta, Inc., San Diego, California., Shaw AT; Massachusetts General Hospital, Boston, Massachusetts., De Braud FG; Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano, Milan, Italy.; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

المصدر: Cancer discovery [Cancer Discov] 2017 Apr; Vol. 7 (4), pp. 400-409. Date of Electronic Publication: 2017 Feb 09.

نوع المنشور: Clinical Trial, Phase II; Journal Article

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE

مواضيع طبية MeSH: Benzamides/*administration & dosage , Carcinoma, Non-Small-Cell Lung/*drug therapy , Colorectal Neoplasms/*drug therapy , Indazoles/*administration & dosage , Mammary Analogue Secretory Carcinoma/*drug therapy , Melanoma/*drug therapy , Oncogene Proteins, Fusion/*antagonists & inhibitors, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anaplastic Lymphoma Kinase ; Benzamides/adverse effects ; Benzamides/pharmacokinetics ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; Crizotinib ; Dose-Response Relationship, Drug ; Female ; Humans ; Indazoles/adverse effects ; Indazoles/pharmacokinetics ; Male ; Mammary Analogue Secretory Carcinoma/genetics ; Melanoma/genetics ; Melanoma/pathology ; Membrane Glycoproteins/antagonists & inhibitors ; Membrane Glycoproteins/genetics ; Middle Aged ; Oncogene Proteins, Fusion/genetics ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacokinetics ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Proto-Oncogene Proteins/antagonists & inhibitors ; Pyrazoles/administration & dosage ; Pyridines/administration & dosage ; Receptor Protein-Tyrosine Kinases/antagonists & inhibitors ; Receptor Protein-Tyrosine Kinases/genetics ; Receptor, trkA/antagonists & inhibitors ; Receptor, trkA/genetics ; Receptor, trkB/antagonists & inhibitors ; Receptor, trkB/genetics ; Receptor, trkC/antagonists & inhibitors ; Receptor, trkC/genetics ; Sequestosome-1 Protein/genetics